Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Haematologica Année : 2018

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)

(1) , (1) , (2) , (3) , (4) , (5) , (1) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13

Résumé

No abstract available

Dates et versions

hal-03605023 , version 1 (10-03-2022)

Identifiants

Citer

Ramy Rahme, Lionel Ades, Xavier Thomas, Agnes Guerci-Bresler, Arnaud Pigneux, et al.. Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial). Haematologica, 2018, 103 (11), pp.E519-E521. ⟨10.3324/haematol.2018.193151⟩. ⟨hal-03605023⟩
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More